Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 69atezolizumab 54lenvatinib 42durvalumab 42Nivolumab 38pembrolizumab 35tremelimumab 28Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Blood Cell Count × 1 year × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡